JSM 2015 Preliminary Program

Online Program Home
My Program

Legend: Washington State Convention Center = CC, Sheraton Seattle = S, Grand Hyatt = GH and The Conference Center = TCC
* = applied session       ! = JSM meeting theme

Activity Details
680 * ! Thu, 8/13/2015, 10:30 AM - 12:20 PM CC-611
Benefit-Risk Assessment to Support Decision-Making in Drug Development and Regulatory Assessment — Topic Contributed Papers
Biopharmaceutical Section , Committee on Applied Statisticians
Organizer(s): Bo Fu, AbbVie
Chair(s): Bo Fu, AbbVie
10:35 AM Two Statistical Approaches to Incorporate Data Uncertainty into Multiple Criteria Decision Analysis (MCDA) for Benefit-Risk Assessment of Medical Products — Shihua Wen, AbbVie
10:55 AM The Influence of Clinically and Statistically Meaningful Differences in Risk Benefit: A Case Study of the First Approved Allergenic Sublingual Immunotherapy (SLIT) Products — Tammy Massie
11:15 AM Developing a Benefit-Risk Process That Becomes Fully Integrated into Developmental Processes and Decision-Making Within a Biopharmaceutical Organization — Mondira Bhattacharya, AbbVie ; Rebecca B. Reindel, AbbVie
11:35 AM Benefit-Risk Assessment in the Absence of Established Definition of Responders — Amarjot Kaur, Merck Research Laboratories ; Ziliang Li, Merck Research Laboratories
11:55 AM Discussant: Jerald Schindler, Merck Research Laboratories
12:15 PM Floor Discussion




For program information, contact the JSM Registration Department or phone (888) 231-3473.

For Professional Development information, contact the Education Department.

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

2015 JSM Online Program Home